A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
复制标题
五 DNA 甲基化特征可作为卵巢浆液性囊腺癌患者的新型预后生物标志物
DOI：
10.1186/s13148-018-0574-0
复制
发表时间：
2018-11-16
影响因子：
5.7
通讯作者：
Wang Q
中科院分区：
文献类型：
--
作者：
Guo W;Zhu L;Yu M;Zhu R;Chen Q;Wang Q
背景卵巢癌是女性生殖系统最致命的肿瘤，在美国女性癌症死亡原因中居第五位。预后差，由于缺乏生物标志物的治疗选项。结果551例卵巢浆液性囊腺癌（OSC）在癌症基因组图谱（TCGA）数据库中的甲基化阵列数据进行了评估，在这项研究中，探讨甲基化生物标志物与预后，改善患者的预后。这些患者被分为训练数据集（前三分之二）和验证数据集（剩下的三分之一）。在训练数据集中使用考克斯回归分析发现五DNA甲基化特征与OSC患者的总体生存率显著相关。Kaplan-Meier分析表明，在训练集和验证集中，五个DNA甲基化特征可以显着区分高风险和低风险患者。受试者工作特征（ROC）分析进一步证实，5-DNA甲基化标记对预测患者的预后生存具有较高的敏感性和特异性。此外，5-DNA甲基化标记不仅适用于不同年龄、阶段、组织学分级的患者，和手术后残留肿瘤的大小，而且与已知的生物标志物相比，在预测OSC预后方面更准确。DNA甲基化标志物有可能成为一种新的独立的预后指标，并作为指导临床治疗以改善预后的重要工具对患者进行预测和管理。因此，本研究的结果可能具有潜在的临床意义。
BackgroundOvarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options.ResultsThe methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers.ConclusionsThis five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.
登录
查看更多内容
DOI：
10.1038/nrclinonc.2013.5
发表时间：
2013-04
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
通讯作者：
--
PTEN抑制RAC1的prex2催化活化以限制肿瘤细胞侵袭。
影响因子：
7.3
作者：
Mense SM;Barrows D;Hodakoski C;Steinbach N;Schoenfeld D;Su W;Hopkins BD;Su T;Fine B;Hibshoosh H;Parsons R
通讯作者：
Parsons R
DOI：
10.1158/1078-0432.ccr-15-1669
发表时间：
2016-06-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Bonito NA;Borley J;Wilhelm-Benartzi CS;Ghaem-Maghami S;Brown R
通讯作者：
Brown R
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
4.7
作者：
Chi, Dennis S.;Eisenhauer, Eric L.;Barakat, Richard R.
通讯作者：
Barakat, Richard R.